APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mirabegron Sustained-release Tablets

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Mirabegron Sustained-release Tablets Market Analysis and Forecast 2026-2032

27 December 2025195 pages

Choose your research edition.

Industry ResearchMirabegron Sustained-release Tablets Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Mirabegron Sustained-release Tablets Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Mirabegron Sustained-release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mirabegron Sustained-release Tablets Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Mirabegron Sustained-release Tablets Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Mirabegron Sustained-release Tablets market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Mirabegron Sustained-release Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Mirabegron Sustained-release Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Mirabegron Sustained-release Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Mirabegron Sustained-release Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Mirabegron Sustained-release Tablets include Alkem Laboratories, Astellas Pharma, Lupin Pharmaceuticals, Zydus Lifesciences, China Resources Pharmaceutical, Jiangsu Huayang Pharmaceutical, Jiangxi Shanxiang Pharmaceutical, Qilu Pharmaceutical and Shenzhen Main Luck Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Mirabegron Sustained-release Tablets, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Mirabegron Sustained-release Tablets, also provides the sales of main regions and countries. Of the upcoming market potential for Mirabegron Sustained-release Tablets, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Mirabegron Sustained-release Tablets sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Mirabegron Sustained-release Tablets market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Mirabegron Sustained-release Tablets sales, projected growth trends, production technology, application and end-user industry.

Mirabegron Sustained-release Tablets Segment by Company

Alkem Laboratories

Astellas Pharma

Lupin Pharmaceuticals

Zydus Lifesciences

China Resources Pharmaceutical

Jiangsu Huayang Pharmaceutical

Jiangxi Shanxiang Pharmaceutical

Qilu Pharmaceutical

Shenzhen Main Luck Pharmaceuticals

CSPC Pharmaceutical

Sichuan Gowell Pharmaceutical

Zhejiang Huayi Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Mirabegron Sustained-release Tablets Segment by Type

25mg per Tablet

50mg per Tablet

Mirabegron Sustained-release Tablets Segment by Application

Hospital and Clinic

Pharmacy

Other

Mirabegron Sustained-release Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mirabegron Sustained-release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mirabegron Sustained-release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mirabegron Sustained-release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Mirabegron Sustained-release Tablets in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Mirabegron Sustained-release Tablets manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Mirabegron Sustained-release Tablets sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Mirabegron Sustained-release Tablets Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 25mg per Tablet Major Manufacturers Table 3. 50mg per Tablet Major Manufacturers Table 4. Global Mirabegron Sustained-release Tablets Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital and Clinic Major Manufacturers Table 6. Pharmacy Major Manufacturers Table 7. Other Major Manufacturers Table 8. Mirabegron Sustained-release Tablets Industry Trends Table 9. Mirabegron Sustained-release Tablets Industry Drivers Table 10. Mirabegron Sustained-release Tablets Industry Opportunities and Challenges Table 11. Mirabegron Sustained-release Tablets Industry Restraints Table 12. Global Mirabegron Sustained-release Tablets Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Mirabegron Sustained-release Tablets Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Mirabegron Sustained-release Tablets Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Mirabegron Sustained-release Tablets Revenue Market Share by Region (2021-2026) Table 16. Global Mirabegron Sustained-release Tablets Revenue Market Share by Region (2027-2032) Table 17. Global Mirabegron Sustained-release Tablets Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Mirabegron Sustained-release Tablets Sales by Region (2021-2026) & (K Units) Table 19. Global Mirabegron Sustained-release Tablets Sales by Region (2027-2032) & (K Units) Table 20. Global Mirabegron Sustained-release Tablets Sales Market Share by Region (2021-2026) Table 21. Global Mirabegron Sustained-release Tablets Sales Market Share by Region (2027-2032) Table 22. Global Mirabegron Sustained-release Tablets Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Mirabegron Sustained-release Tablets Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Mirabegron Sustained-release Tablets Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Mirabegron Sustained-release Tablets Sales Market Share by Manufacturers (2021-2026) Table 26. Global Mirabegron Sustained-release Tablets Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Mirabegron Sustained-release Tablets Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Mirabegron Sustained-release Tablets Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Mirabegron Sustained-release Tablets Manufacturers, Product Type & Application Table 30. Global Mirabegron Sustained-release Tablets Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Mirabegron Sustained-release Tablets by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Mirabegron Sustained-release Tablets Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Mirabegron Sustained-release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Mirabegron Sustained-release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2021-2026) Table 37. Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2027-2032) Table 38. Global Mirabegron Sustained-release Tablets Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 40. Global Mirabegron Sustained-release Tablets Sales by Type (2027-2032) & (K Units) Table 41. Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2026) Table 42. Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2027-2032) Table 43. Global Mirabegron Sustained-release Tablets Price by Type (2021-2026) & (US$/Unit) Table 44. Global Mirabegron Sustained-release Tablets Price by Type (2027-2032) & (US$/Unit) Table 45. Global Mirabegron Sustained-release Tablets Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Mirabegron Sustained-release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Mirabegron Sustained-release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2021-2026) Table 49. Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2027-2032) Table 50. Global Mirabegron Sustained-release Tablets Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 52. Global Mirabegron Sustained-release Tablets Sales by Application (2027-2032) & (K Units) Table 53. Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2021-2026) Table 54. Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2027-2032) Table 55. Global Mirabegron Sustained-release Tablets Price by Application (2021-2026) & (US$/Unit) Table 56. Global Mirabegron Sustained-release Tablets Price by Application (2027-2032) & (US$/Unit) Table 57. Alkem Laboratories Company Information Table 58. Alkem Laboratories Business Overview Table 59. Alkem Laboratories Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolio Table 61. Alkem Laboratories Recent Development Table 62. Astellas Pharma Company Information Table 63. Astellas Pharma Business Overview Table 64. Astellas Pharma Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolio Table 66. Astellas Pharma Recent Development Table 67. Lupin Pharmaceuticals Company Information Table 68. Lupin Pharmaceuticals Business Overview Table 69. Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio Table 71. Lupin Pharmaceuticals Recent Development Table 72. Zydus Lifesciences Company Information Table 73. Zydus Lifesciences Business Overview Table 74. Zydus Lifesciences Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolio Table 76. Zydus Lifesciences Recent Development Table 77. China Resources Pharmaceutical Company Information Table 78. China Resources Pharmaceutical Business Overview Table 79. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 81. China Resources Pharmaceutical Recent Development Table 82. Jiangsu Huayang Pharmaceutical Company Information Table 83. Jiangsu Huayang Pharmaceutical Business Overview Table 84. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 86. Jiangsu Huayang Pharmaceutical Recent Development Table 87. Jiangxi Shanxiang Pharmaceutical Company Information Table 88. Jiangxi Shanxiang Pharmaceutical Business Overview Table 89. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 91. Jiangxi Shanxiang Pharmaceutical Recent Development Table 92. Qilu Pharmaceutical Company Information Table 93. Qilu Pharmaceutical Business Overview Table 94. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 96. Qilu Pharmaceutical Recent Development Table 97. Shenzhen Main Luck Pharmaceuticals Company Information Table 98. Shenzhen Main Luck Pharmaceuticals Business Overview Table 99. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio Table 101. Shenzhen Main Luck Pharmaceuticals Recent Development Table 102. CSPC Pharmaceutical Company Information Table 103. CSPC Pharmaceutical Business Overview Table 104. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 106. CSPC Pharmaceutical Recent Development Table 107. Sichuan Gowell Pharmaceutical Company Information Table 108. Sichuan Gowell Pharmaceutical Business Overview Table 109. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 111. Sichuan Gowell Pharmaceutical Recent Development Table 112. Zhejiang Huayi Pharmaceutical Company Information Table 113. Zhejiang Huayi Pharmaceutical Business Overview Table 114. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 116. Zhejiang Huayi Pharmaceutical Recent Development Table 117. Chia Tai Tianqing Pharmaceutical Company Information Table 118. Chia Tai Tianqing Pharmaceutical Business Overview Table 119. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 121. Chia Tai Tianqing Pharmaceutical Recent Development Table 122. North America Mirabegron Sustained-release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 123. North America Mirabegron Sustained-release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 124. North America Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 125. North America Mirabegron Sustained-release Tablets Sales by Type (2027-2032) & (K Units) Table 126. North America Mirabegron Sustained-release Tablets Sales Price by Type (2021-2026) & (US$/Unit) Table 127. North America Mirabegron Sustained-release Tablets Sales Price by Type (2027-2032) & (US$/Unit) Table 128. North America Mirabegron Sustained-release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 129. North America Mirabegron Sustained-release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 130. North America Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 131. North America Mirabegron Sustained-release Tablets Sales by Application (2027-2032) & (K Units) Table 132. North America Mirabegron Sustained-release Tablets Sales Price by Application (2021-2026) & (US$/Unit) Table 133. North America Mirabegron Sustained-release Tablets Sales Price by Application (2027-2032) & (US$/Unit) Table 134. North America Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. North America Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 136. North America Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 137. North America Mirabegron Sustained-release Tablets Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 138. North America Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 139. North America Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 140. North America Mirabegron Sustained-release Tablets Sales Price by Country (2021-2026) & (US$/Unit) Table 141. North America Mirabegron Sustained-release Tablets Sales Price by Country (2027-2032) & (US$/Unit) Table 142. United States Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 143. Canada Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 144. Mexico Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 145. Europe Mirabegron Sustained-release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 146. Europe Mirabegron Sustained-release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 147. Europe Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 148. Europe Mirabegron Sustained-release Tablets Sales by Type (2027-2032) & (K Units) Table 149. Europe Mirabegron Sustained-release Tablets Sales Price by Type (2021-2026) & (US$/Unit) Table 150. Europe Mirabegron Sustained-release Tablets Sales Price by Type (2027-2032) & (US$/Unit) Table 151. Europe Mirabegron Sustained-release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 152. Europe Mirabegron Sustained-release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 153. Europe Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 154. Europe Mirabegron Sustained-release Tablets Sales by Application (2027-2032) & (K Units) Table 155. Europe Mirabegron Sustained-release Tablets Sales Price by Application (2021-2026) & (US$/Unit) Table 156. Europe Mirabegron Sustained-release Tablets Sales Price by Application (2027-2032) & (US$/Unit) Table 157. Europe Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 158. Europe Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 159. Europe Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 160. Europe Mirabegron Sustained-release Tablets Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 161. Europe Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 162. Europe Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 163. Europe Mirabegron Sustained-release Tablets Sales Price by Country (2021-2026) & (US$/Unit) Table 164. Europe Mirabegron Sustained-release Tablets Sales Price by Country (2027-2032) & (US$/Unit) Table 165. Germany Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 166. France Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 167. U.K. Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 168. Italy Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 169. Russia Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 170. Spain Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 171. Netherlands Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 172. Switzerland Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 173. Sweden Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 174. Poland Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 175. China Mirabegron Sustained-release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 176. China Mirabegron Sustained-release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 177. China Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 178. China Mirabegron Sustained-release Tablets Sales by Type (2027-2032) & (K Units) Table 179. China Mirabegron Sustained-release Tablets Sales Price by Type (2021-2026) & (US$/Unit) Table 180. China Mirabegron Sustained-release Tablets Sales Price by Type (2027-2032) & (US$/Unit) Table 181. China Mirabegron Sustained-release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 182. China Mirabegron Sustained-release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 183. China Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 184. China Mirabegron Sustained-release Tablets Sales by Application (2027-2032) & (K Units) Table 185. China Mirabegron Sustained-release Tablets Sales Price by Application (2021-2026) & (US$/Unit) Table 186. China Mirabegron Sustained-release Tablets Sales Price by Application (2027-2032) & (US$/Unit) Table 187. Asia Mirabegron Sustained-release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 188. Asia Mirabegron Sustained-release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 189. Asia Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 190. Asia Mirabegron Sustained-release Tablets Sales by Type (2027-2032) & (K Units) Table 191. Asia Mirabegron Sustained-release Tablets Sales Price by Type (2021-2026) & (US$/Unit) Table 192. Asia Mirabegron Sustained-release Tablets Sales Price by Type (2027-2032) & (US$/Unit) Table 193. Asia Mirabegron Sustained-release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 194. Asia Mirabegron Sustained-release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 195. Asia Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 196. Asia Mirabegron Sustained-release Tablets Sales by Application (2027-2032) & (K Units) Table 197. Asia Mirabegron Sustained-release Tablets Sales Price by Application (2021-2026) & (US$/Unit) Table 198. Asia Mirabegron Sustained-release Tablets Sales Price by Application (2027-2032) & (US$/Unit) Table 199. Asia Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 200. Asia Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 201. Asia Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 202. Asia Mirabegron Sustained-release Tablets Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 203. Asia Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 204. Asia Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 205. Asia Mirabegron Sustained-release Tablets Sales Price by Country (2021-2026) & (US$/Unit) Table 206. Asia Mirabegron Sustained-release Tablets Sales Price by Country (2027-2032) & (US$/Unit) Table 207. Japan Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 208. South Korea Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 209. India Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 210. Australia Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 211. Taiwan Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 212. Southeast Asia Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 213. SAMEA Mirabegron Sustained-release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 214. SAMEA Mirabegron Sustained-release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 215. SAMEA Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 216. SAMEA Mirabegron Sustained-release Tablets Sales by Type (2027-2032) & (K Units) Table 217. SAMEA Mirabegron Sustained-release Tablets Sales Price by Type (2021-2026) & (US$/Unit) Table 218. SAMEA Mirabegron Sustained-release Tablets Sales Price by Type (2027-2032) & (US$/Unit) Table 219. SAMEA Mirabegron Sustained-release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 220. SAMEA Mirabegron Sustained-release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 221. SAMEA Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 222. SAMEA Mirabegron Sustained-release Tablets Sales by Application (2027-2032) & (K Units) Table 223. SAMEA Mirabegron Sustained-release Tablets Sales Price by Application (2021-2026) & (US$/Unit) Table 224. SAMEA Mirabegron Sustained-release Tablets Sales Price by Application (2027-2032) & (US$/Unit) Table 225. SAMEA Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 226. SAMEA Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 227. SAMEA Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 228. SAMEA Mirabegron Sustained-release Tablets Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 229. SAMEA Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 230. SAMEA Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 231. SAMEA Mirabegron Sustained-release Tablets Sales Price by Country (2021-2026) & (US$/Unit) Table 232. SAMEA Mirabegron Sustained-release Tablets Sales Price by Country (2027-2032) & (US$/Unit) Table 233. Brazil Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 234. Argentina Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 235. Chile Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 236. Colombia Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 237. Peru Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 238. Saudi Arabia Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 239. Israel Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 240. UAE Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 241. Turkey Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 242. Iran Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 243. Egypt Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Table 244. Key Raw Materials Table 245. Raw Materials Key Suppliers Table 246. Mirabegron Sustained-release Tablets Distributors List Table 247. Mirabegron Sustained-release Tablets Customers List Table 248. Research Programs/Design for This Report Table 249. Authors List of This Report Table 250. Secondary Sources Table 251. Primary Sources List of Figures Figure 1. Mirabegron Sustained-release Tablets Image Figure 2. Global Mirabegron Sustained-release Tablets Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mirabegron Sustained-release Tablets Market Size Share 2021 VS 2025 VS 2032 Figure 4. 25mg per Tablet Image Figure 5. 50mg per Tablet Image Figure 6. Global Mirabegron Sustained-release Tablets Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Mirabegron Sustained-release Tablets Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital and Clinic Image Figure 9. Pharmacy Image Figure 10. Other Image Figure 11. Global Mirabegron Sustained-release Tablets Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Mirabegron Sustained-release Tablets Revenue (2021-2032) & (US$ Million) Figure 13. Global Mirabegron Sustained-release Tablets Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Mirabegron Sustained-release Tablets Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Mirabegron Sustained-release Tablets Revenue Market Share by Region (2021-2032) Figure 16. Global Mirabegron Sustained-release Tablets Sales (2021-2032) & (K Units) Figure 17. Global Mirabegron Sustained-release Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Mirabegron Sustained-release Tablets Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Mirabegron Sustained-release Tablets Sales YoY (2021-2032) & (K Units) Figure 20. Europe Mirabegron Sustained-release Tablets Sales YoY (2021-2032) & (K Units) Figure 21. China Mirabegron Sustained-release Tablets Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Mirabegron Sustained-release Tablets Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Mirabegron Sustained-release Tablets Sales YoY (2021-2032) & (K Units) Figure 24. Global Mirabegron Sustained-release Tablets Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Mirabegron Sustained-release Tablets Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Mirabegron Sustained-release Tablets Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Mirabegron Sustained-release Tablets Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2021-2032) Figure 30. Global Mirabegron Sustained-release Tablets Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Mirabegron Sustained-release Tablets Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2032) Figure 33. Global Mirabegron Sustained-release Tablets Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Mirabegron Sustained-release Tablets Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2021-2032) Figure 36. Global Mirabegron Sustained-release Tablets Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Mirabegron Sustained-release Tablets Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2021-2032) Figure 39. North America Mirabegron Sustained-release Tablets Revenue Share by Type (2021-2032) Figure 40. North America Mirabegron Sustained-release Tablets Sales Share by Type (2021-2032) Figure 41. North America Mirabegron Sustained-release Tablets Revenue Share by Application (2021-2032) Figure 42. North America Mirabegron Sustained-release Tablets Sales Share by Application (2021-2032) Figure 43. North America Mirabegron Sustained-release Tablets Revenue Share by Country (2021-2032) Figure 44. North America Mirabegron Sustained-release Tablets Sales Share by Country (2021-2032) Figure 45. Europe Mirabegron Sustained-release Tablets Revenue Share by Type (2021-2032) Figure 46. Europe Mirabegron Sustained-release Tablets Sales Share by Type (2021-2032) Figure 47. Europe Mirabegron Sustained-release Tablets Revenue Share by Application (2021-2032) Figure 48. Europe Mirabegron Sustained-release Tablets Sales Share by Application (2021-2032) Figure 49. Europe Mirabegron Sustained-release Tablets Revenue Share by Country (2021-2032) Figure 50. Europe Mirabegron Sustained-release Tablets Sales Share by Country (2021-2032) Figure 51. China Mirabegron Sustained-release Tablets Revenue Share by Type (2021-2032) Figure 52. China Mirabegron Sustained-release Tablets Sales Share by Type (2021-2032) Figure 53. China Mirabegron Sustained-release Tablets Revenue Share by Application (2021-2032) Figure 54. China Mirabegron Sustained-release Tablets Sales Share by Application (2021-2032) Figure 55. Asia Mirabegron Sustained-release Tablets Revenue Share by Type (2021-2032) Figure 56. Asia Mirabegron Sustained-release Tablets Sales Share by Type (2021-2032) Figure 57. Asia Mirabegron Sustained-release Tablets Revenue Share by Application (2021-2032) Figure 58. Asia Mirabegron Sustained-release Tablets Sales Share by Application (2021-2032) Figure 59. Asia Mirabegron Sustained-release Tablets Revenue Share by Country (2021-2032) Figure 60. Asia Mirabegron Sustained-release Tablets Sales Share by Country (2021-2032) Figure 61. SAMEA Mirabegron Sustained-release Tablets Revenue Share by Type (2021-2032) Figure 62. SAMEA Mirabegron Sustained-release Tablets Sales Share by Type (2021-2032) Figure 63. SAMEA Mirabegron Sustained-release Tablets Revenue Share by Application (2021-2032) Figure 64. SAMEA Mirabegron Sustained-release Tablets Sales Share by Application (2021-2032) Figure 65. SAMEA Mirabegron Sustained-release Tablets Revenue Share by Country (2021-2032) Figure 66. SAMEA Mirabegron Sustained-release Tablets Sales Share by Country (2021-2032) Figure 67. Mirabegron Sustained-release Tablets Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Mirabegron Sustained-release Tablets Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • 25mg per Tablet
  • 50mg per Tablet
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Alkem Laboratories
  • Astellas Pharma
  • Lupin Pharmaceuticals
  • Zydus Lifesciences
  • China Resources Pharmaceutical
  • Jiangsu Huayang Pharmaceutical
  • Jiangxi Shanxiang Pharmaceutical
  • Qilu Pharmaceutical
  • Shenzhen Main Luck Pharmaceuticals
  • CSPC Pharmaceutical
  • Sichuan Gowell Pharmaceutical
  • Zhejiang Huayi Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Mirabegron Sustained-release Tablets Market by Type
  3. 1.2.1 Global Mirabegron Sustained-release Tablets Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 25mg per Tablet
  5. 1.2.3 50mg per Tablet
  6. 1.3 Mirabegron Sustained-release Tablets Market by Application
  7. 1.3.1 Global Mirabegron Sustained-release Tablets Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital and Clinic
  9. 1.3.3 Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Mirabegron Sustained-release Tablets Market Dynamics
  1. 2.1 Mirabegron Sustained-release Tablets Industry Trends
  2. 2.2 Mirabegron Sustained-release Tablets Industry Drivers
  3. 2.3 Mirabegron Sustained-release Tablets Industry Opportunities and Challenges
  4. 2.4 Mirabegron Sustained-release Tablets Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Mirabegron Sustained-release Tablets Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Mirabegron Sustained-release Tablets Revenue by Region
  3. 3.2.1 Global Mirabegron Sustained-release Tablets Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Mirabegron Sustained-release Tablets Revenue by Region (2021-2026)
  5. 3.2.3 Global Mirabegron Sustained-release Tablets Revenue by Region (2027-2032)
  6. 3.2.4 Global Mirabegron Sustained-release Tablets Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Mirabegron Sustained-release Tablets Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Mirabegron Sustained-release Tablets Sales by Region
  9. 3.4.1 Global Mirabegron Sustained-release Tablets Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Mirabegron Sustained-release Tablets Sales by Region (2021-2026)
  11. 3.4.3 Global Mirabegron Sustained-release Tablets Sales by Region (2027-2032)
  12. 3.4.4 Global Mirabegron Sustained-release Tablets Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Mirabegron Sustained-release Tablets Revenue by Manufacturers
  2. 4.1.1 Global Mirabegron Sustained-release Tablets Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Mirabegron Sustained-release Tablets Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Mirabegron Sustained-release Tablets Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Mirabegron Sustained-release Tablets Sales by Manufacturers
  6. 4.2.1 Global Mirabegron Sustained-release Tablets Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Mirabegron Sustained-release Tablets Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Mirabegron Sustained-release Tablets Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Mirabegron Sustained-release Tablets Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Mirabegron Sustained-release Tablets Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Mirabegron Sustained-release Tablets Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Mirabegron Sustained-release Tablets Manufacturers, Product Type & Application
  13. 4.7 Global Mirabegron Sustained-release Tablets Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Mirabegron Sustained-release Tablets Market CR5 and HHI
  16. 4.8.2 2025 Mirabegron Sustained-release Tablets Tier 1, Tier 2, and Tier 3
5 Mirabegron Sustained-release Tablets Market by Type
  1. 5.1 Global Mirabegron Sustained-release Tablets Revenue by Type
  2. 5.1.1 Global Mirabegron Sustained-release Tablets Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Mirabegron Sustained-release Tablets Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Mirabegron Sustained-release Tablets Sales by Type
  6. 5.2.1 Global Mirabegron Sustained-release Tablets Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Mirabegron Sustained-release Tablets Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2032)
  9. 5.3 Global Mirabegron Sustained-release Tablets Price by Type
6 Mirabegron Sustained-release Tablets Market by Application
  1. 6.1 Global Mirabegron Sustained-release Tablets Revenue by Application
  2. 6.1.1 Global Mirabegron Sustained-release Tablets Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Mirabegron Sustained-release Tablets Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Mirabegron Sustained-release Tablets Sales by Application
  6. 6.2.1 Global Mirabegron Sustained-release Tablets Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Mirabegron Sustained-release Tablets Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2021-2032)
  9. 6.3 Global Mirabegron Sustained-release Tablets Price by Application
7 Company Profiles
  1. 7.1 Alkem Laboratories
  2. 7.1.1 Alkem Laboratories Company Information
  3. 7.1.2 Alkem Laboratories Business Overview
  4. 7.1.3 Alkem Laboratories Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolio
  6. 7.1.5 Alkem Laboratories Recent Developments
  7. 7.2 Astellas Pharma
  8. 7.2.1 Astellas Pharma Company Information
  9. 7.2.2 Astellas Pharma Business Overview
  10. 7.2.3 Astellas Pharma Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolio
  12. 7.2.5 Astellas Pharma Recent Developments
  13. 7.3 Lupin Pharmaceuticals
  14. 7.3.1 Lupin Pharmaceuticals Company Information
  15. 7.3.2 Lupin Pharmaceuticals Business Overview
  16. 7.3.3 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
  18. 7.3.5 Lupin Pharmaceuticals Recent Developments
  19. 7.4 Zydus Lifesciences
  20. 7.4.1 Zydus Lifesciences Company Information
  21. 7.4.2 Zydus Lifesciences Business Overview
  22. 7.4.3 Zydus Lifesciences Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolio
  24. 7.4.5 Zydus Lifesciences Recent Developments
  25. 7.5 China Resources Pharmaceutical
  26. 7.5.1 China Resources Pharmaceutical Company Information
  27. 7.5.2 China Resources Pharmaceutical Business Overview
  28. 7.5.3 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  30. 7.5.5 China Resources Pharmaceutical Recent Developments
  31. 7.6 Jiangsu Huayang Pharmaceutical
  32. 7.6.1 Jiangsu Huayang Pharmaceutical Company Information
  33. 7.6.2 Jiangsu Huayang Pharmaceutical Business Overview
  34. 7.6.3 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  36. 7.6.5 Jiangsu Huayang Pharmaceutical Recent Developments
  37. 7.7 Jiangxi Shanxiang Pharmaceutical
  38. 7.7.1 Jiangxi Shanxiang Pharmaceutical Company Information
  39. 7.7.2 Jiangxi Shanxiang Pharmaceutical Business Overview
  40. 7.7.3 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  42. 7.7.5 Jiangxi Shanxiang Pharmaceutical Recent Developments
  43. 7.8 Qilu Pharmaceutical
  44. 7.8.1 Qilu Pharmaceutical Company Information
  45. 7.8.2 Qilu Pharmaceutical Business Overview
  46. 7.8.3 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  48. 7.8.5 Qilu Pharmaceutical Recent Developments
  49. 7.9 Shenzhen Main Luck Pharmaceuticals
  50. 7.9.1 Shenzhen Main Luck Pharmaceuticals Company Information
  51. 7.9.2 Shenzhen Main Luck Pharmaceuticals Business Overview
  52. 7.9.3 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
  54. 7.9.5 Shenzhen Main Luck Pharmaceuticals Recent Developments
  55. 7.10 CSPC Pharmaceutical
  56. 7.10.1 CSPC Pharmaceutical Company Information
  57. 7.10.2 CSPC Pharmaceutical Business Overview
  58. 7.10.3 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  60. 7.10.5 CSPC Pharmaceutical Recent Developments
  61. 7.11 Sichuan Gowell Pharmaceutical
  62. 7.11.1 Sichuan Gowell Pharmaceutical Company Information
  63. 7.11.2 Sichuan Gowell Pharmaceutical Business Overview
  64. 7.11.3 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  66. 7.11.5 Sichuan Gowell Pharmaceutical Recent Developments
  67. 7.12 Zhejiang Huayi Pharmaceutical
  68. 7.12.1 Zhejiang Huayi Pharmaceutical Company Information
  69. 7.12.2 Zhejiang Huayi Pharmaceutical Business Overview
  70. 7.12.3 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  72. 7.12.5 Zhejiang Huayi Pharmaceutical Recent Developments
  73. 7.13 Chia Tai Tianqing Pharmaceutical
  74. 7.13.1 Chia Tai Tianqing Pharmaceutical Company Information
  75. 7.13.2 Chia Tai Tianqing Pharmaceutical Business Overview
  76. 7.13.3 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  78. 7.13.5 Chia Tai Tianqing Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Mirabegron Sustained-release Tablets Market Size by Type
  2. 8.1.1 North America Mirabegron Sustained-release Tablets Revenue by Type (2021-2032)
  3. 8.1.2 North America Mirabegron Sustained-release Tablets Sales by Type (2021-2032)
  4. 8.1.3 North America Mirabegron Sustained-release Tablets Price by Type (2021-2032)
  5. 8.2 North America Mirabegron Sustained-release Tablets Market Size by Application
  6. 8.2.1 North America Mirabegron Sustained-release Tablets Revenue by Application (2021-2032)
  7. 8.2.2 North America Mirabegron Sustained-release Tablets Sales by Application (2021-2032)
  8. 8.2.3 North America Mirabegron Sustained-release Tablets Price by Application (2021-2032)
  9. 8.3 North America Mirabegron Sustained-release Tablets Market Size by Country
  10. 8.3.1 North America Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Mirabegron Sustained-release Tablets Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Mirabegron Sustained-release Tablets Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Mirabegron Sustained-release Tablets Market Size by Type
  2. 9.1.1 Europe Mirabegron Sustained-release Tablets Revenue by Type (2021-2032)
  3. 9.1.2 Europe Mirabegron Sustained-release Tablets Sales by Type (2021-2032)
  4. 9.1.3 Europe Mirabegron Sustained-release Tablets Price by Type (2021-2032)
  5. 9.2 Europe Mirabegron Sustained-release Tablets Market Size by Application
  6. 9.2.1 Europe Mirabegron Sustained-release Tablets Revenue by Application (2021-2032)
  7. 9.2.2 Europe Mirabegron Sustained-release Tablets Sales by Application (2021-2032)
  8. 9.2.3 Europe Mirabegron Sustained-release Tablets Price by Application (2021-2032)
  9. 9.3 Europe Mirabegron Sustained-release Tablets Market Size by Country
  10. 9.3.1 Europe Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Mirabegron Sustained-release Tablets Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Mirabegron Sustained-release Tablets Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Mirabegron Sustained-release Tablets Market Size by Type
  2. 10.1.1 China Mirabegron Sustained-release Tablets Revenue by Type (2021-2032)
  3. 10.1.2 China Mirabegron Sustained-release Tablets Sales by Type (2021-2032)
  4. 10.1.3 China Mirabegron Sustained-release Tablets Price by Type (2021-2032)
  5. 10.2 China Mirabegron Sustained-release Tablets Market Size by Application
  6. 10.2.1 China Mirabegron Sustained-release Tablets Revenue by Application (2021-2032)
  7. 10.2.2 China Mirabegron Sustained-release Tablets Sales by Application (2021-2032)
  8. 10.2.3 China Mirabegron Sustained-release Tablets Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Mirabegron Sustained-release Tablets Market Size by Type
  2. 11.1.1 Asia Mirabegron Sustained-release Tablets Revenue by Type (2021-2032)
  3. 11.1.2 Asia Mirabegron Sustained-release Tablets Sales by Type (2021-2032)
  4. 11.1.3 Asia Mirabegron Sustained-release Tablets Price by Type (2021-2032)
  5. 11.2 Asia Mirabegron Sustained-release Tablets Market Size by Application
  6. 11.2.1 Asia Mirabegron Sustained-release Tablets Revenue by Application (2021-2032)
  7. 11.2.2 Asia Mirabegron Sustained-release Tablets Sales by Application (2021-2032)
  8. 11.2.3 Asia Mirabegron Sustained-release Tablets Price by Application (2021-2032)
  9. 11.3 Asia Mirabegron Sustained-release Tablets Market Size by Country
  10. 11.3.1 Asia Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Mirabegron Sustained-release Tablets Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Mirabegron Sustained-release Tablets Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Mirabegron Sustained-release Tablets Market Size by Type
  2. 12.1.1 SAMEA Mirabegron Sustained-release Tablets Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Mirabegron Sustained-release Tablets Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Mirabegron Sustained-release Tablets Price by Type (2021-2032)
  5. 12.2 SAMEA Mirabegron Sustained-release Tablets Market Size by Application
  6. 12.2.1 SAMEA Mirabegron Sustained-release Tablets Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Mirabegron Sustained-release Tablets Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Mirabegron Sustained-release Tablets Price by Application (2021-2032)
  9. 12.3 SAMEA Mirabegron Sustained-release Tablets Market Size by Country
  10. 12.3.1 SAMEA Mirabegron Sustained-release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Mirabegron Sustained-release Tablets Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Mirabegron Sustained-release Tablets Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Mirabegron Sustained-release Tablets Value Chain Analysis
  2. 13.1.1 Mirabegron Sustained-release Tablets Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Mirabegron Sustained-release Tablets Production Mode & Process
  6. 13.2 Mirabegron Sustained-release Tablets Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Mirabegron Sustained-release Tablets Distributors
  9. 13.2.3 Mirabegron Sustained-release Tablets Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst